13F Filings History of Inspire Investing, LLC

Latest 13F report
Q4 2025 - 17 Feb 2026
Value $
$1,111,390,912
Signature - Title
Will Clark - Director
Location
Meridian, ID
Summary
This page shows a list of all the recent 13F filings made by Inspire Investing, LLC. Form 13F is required to be filed within 45 days of the end of a calendar quarter. Inspire Investing, LLC reported 1104 stock holdings with total value $1,111,390,912 as of Q4 2025. Top holdings included CAT, APH, KLAC, SCHO, and IBD.

Notify me when Inspire Investing, LLC files a new 13F portfolio report.

⭐ Subscribe ⭐
Holdings Value
Quarter Holdings Value $ Bought Sold Net Top Holdings Form Type Filing Time
Q4 2025 1,104 $1,111,390,912 +$253,302,205 -$172,378,234 +$80,923,971 CAT, APH, KLAC, SCHO, IBD 13F-HR 17 Feb 2026, 09:30
Q3 2025 846 $1,027,387,702 +$176,652,876 -$140,623,768 +$36,029,108 CAT, ANET, APH, SCHO, IBD 13F-HR 15 Oct 2025, 15:37
Q2 2025 824 $917,957,751 +$166,451,957 -$139,276,354 +$27,175,603 CAT, WWJD, SCHO, PGR, APH 13F-HR 24 Jul 2025, 16:10
Q1 2025 800 $841,290,999 +$170,395,447 -$194,801,106 -$24,405,659 SCHO, PGR, WWJD, CAT, IBD 13F-HR 03 Jun 2025, 13:40
Q4 2024 824 $893,587,915 +$99,310,708 -$154,976,914 -$55,666,206 USFR, ISRG, CAT, WWJD, ANET 13F-HR 17 Jan 2025, 16:13
Q3 2024 827 $977,493,547 +$210,656,741 -$150,498,639 +$60,158,102 SMCI, IBD, CAT, USFR, ISRG 13F-HR 10 Oct 2024, 15:44
Q2 2024 802 $867,646,672 +$93,542,677 -$171,097,579 -$77,554,902 IBD, USFR, CAT, ISRG, WWJD 13F-HR 12 Aug 2024, 17:01
Q1 2024 792 $977,358,548 +$176,130,353 -$174,561,535 +$1,568,818 CAT, USFR, ISRG, IBD, PGR 13F-HR 07 May 2024, 16:51
Q4 2023 785 $909,261,228 +$127,943,935 -$87,570,956 +$40,372,979 IBD, USFR, CAT, NOW, WWJD 13F-HR 12 Feb 2024, 14:43
Q3 2023 791 $783,231,882 +$147,961,195 -$156,492,925 -$8,531,730 IBD, USFR, CAT, NOW, PLD 13F-HR 26 Oct 2023, 11:59
Q2 2023 788 $826,677,093 +$130,440,620 -$120,200,844 +$10,239,776 IBD, USFR, ISRG, PLD, NOW 13F-HR 31 Jul 2023, 10:23
Q1 2023 782 $785,805,315 +$116,133,024 -$142,023,007 -$25,889,983 USFR, IBD, PLD, ADI, NOW 13F-HR 24 Apr 2023, 10:24
Q4 2022 743 $777,062,322 +$82,947,137 -$61,451,376 +$21,495,761 TFLO, USFR, IBD, WWJD, BLES 13F-HR 26 Jan 2023, 14:28
Q3 2022 754 $707,779,000 +$137,642,915 -$155,111,720 -$17,468,805 USFR, TFLO, IBD, UUP, WWJD 13F-HR 07 Nov 2022, 17:01
Q2 2022 762 $753,659,000 +$170,667,072 -$154,726,857 +$15,940,215 USFR, IBD, UUP, WWJD, BLES 13F-HR 10 Aug 2022, 12:37
Q1 2022 788 $864,069,000 +$154,729,768 -$102,115,596 +$52,614,172 VGSH, IBD, PHYS, BLES, WWJD 13F-HR 21 Apr 2022, 10:10
Q4 2021 786 $872,157,000 +$120,957,252 -$78,622,234 +$42,335,018 IBD, VGLT, ISRG, NOW, PLD Restatement 14 Feb 2022, 10:02
Q3 2021 794 $791,140,000 +$422,059,162 -$358,578,790 +$63,480,372 IBD, VGLT, ISRG, NOW, BLES 13F-HR 09 Nov 2021, 14:02
Q2 2021 593 $759,958,000 +$113,305,915 -$48,632,967 +$64,672,948 NVDA, IBD, BLES, VGLT, ISMD 13F-HR 10 Aug 2021, 16:58
Q1 2021 597 $652,117,000 +$237,021,166 -$75,886,952 +$161,134,214 NVDA, IBD, VGIT, BLES, ISMD 13F-HR 30 Apr 2021, 12:07
Q4 2020 622 $452,176,000 +$140,049,608 -$98,934,454 +$41,115,154 IBD, BLES, NVDA, ISMD, WWJD 13F-HR 12 Feb 2021, 14:47
Q3 2020 432 $363,409,000 +$119,251,970 -$60,630,488 +$58,621,482 VGIT, IBD, BLES, NVDA, WWJD 13F-HR 16 Nov 2020, 16:27
Q2 2020 485 $289,563,000 +$60,285,669 -$64,577,155 -$4,291,486 IBD, BLES, WWJD, ISMD, BIBL 13F-HR 12 Aug 2020, 15:46
Q1 2020 739 $250,317,000 +$76,444,323 -$43,057,826 +$33,386,497 IBD, BLES, WWJD, ISMD, BIBL 13F-HR 08 May 2020, 16:44
Q4 2019 351 $278,872,000 +$20,348,759 -$22,284,519 -$1,935,760 IBD, BLES, ISMD, BIBL, WWJD 13F-HR 24 Jan 2020, 12:28
Q3 2019 375 $262,280,000 +$38,736,964 -$13,395,090 +$25,341,874 IBD, BLES, ISMD, BIBL, UNP 13F-HR 13 Nov 2019, 14:18
Q2 2019 328 $237,739,000 +$29,981,384 -$10,152,116 +$19,829,268 IBD, BLES, ISMD, BIBL, UNP 13F-HR 16 Jul 2019, 13:32
Q1 2019 297 $215,351,000 +$55,953,715 -$9,255,344 +$46,698,371 IBD, BLES, ISMD, BIBL, ABBV 13F-HR 16 May 2019, 07:42
Q4 2018 242 $148,727,000 +$13,982,075 -$4,659,387 +$9,322,688 BLES, IBD, ISMD, BIBL, ABBV Restatement 21 Feb 2019, 18:01
Q3 2018 237 $162,265,000 +$20,782,749 -$3,865,895 +$16,916,854 BLES, IBD, ISMD, BIBL, NVDA Restatement 21 Feb 2019, 17:59
Q2 2018 220 $140,705,000 +$42,082,677 -$1,567,229 +$40,515,448 BLES, IBD, ISMD, BIBL, ABBV Restatement 21 Feb 2019, 17:59
Q1 2018 199 $98,156,000 +$17,351,232 -$35,566,220 -$18,214,988 BLES, IBD, ISMD, BIBL, ITW Restatement 21 Feb 2019, 21:04
Q4 2017 913 $117,527,000 $0 $0 $0 BLES, IBD, ISMD, BIBL, NUE Restatement 21 Feb 2019, 17:49